Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
NNC-04870111 by Novo Nordisk for Obesity: Likelihood of Approval
NNC-04870111 is under clinical development by Novo Nordisk and currently in Phase II for Obesity. According to GlobalData, Phase II...